JP5743905B2 - ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 - Google Patents
ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 Download PDFInfo
- Publication number
- JP5743905B2 JP5743905B2 JP2011547973A JP2011547973A JP5743905B2 JP 5743905 B2 JP5743905 B2 JP 5743905B2 JP 2011547973 A JP2011547973 A JP 2011547973A JP 2011547973 A JP2011547973 A JP 2011547973A JP 5743905 B2 JP5743905 B2 JP 5743905B2
- Authority
- JP
- Japan
- Prior art keywords
- dtpa
- dextran
- sodium
- formulation
- mannosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 86
- 229920002307 Dextran Polymers 0.000 title claims description 84
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 title claims description 26
- 238000000163 radioactive labelling Methods 0.000 title description 18
- 229960003330 pentetic acid Drugs 0.000 title description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 78
- 238000009472 formulation Methods 0.000 claims description 54
- 239000004471 Glycine Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 239000006174 pH buffer Substances 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical group O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 claims description 10
- 239000011261 inert gas Substances 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 150000002840 non-reducing disaccharides Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 6
- 239000002211 L-ascorbic acid Substances 0.000 claims description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 5
- 230000007774 longterm Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical group O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims description 3
- CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 159000000000 sodium salts Chemical group 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- -1 salt dihydrate Chemical class 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 description 46
- 229940088679 drug related substance Drugs 0.000 description 41
- 239000008186 active pharmaceutical agent Substances 0.000 description 40
- 229960002449 glycine Drugs 0.000 description 34
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 25
- 229960005055 sodium ascorbate Drugs 0.000 description 25
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 25
- 229940079593 drug Drugs 0.000 description 24
- 239000003814 drug Substances 0.000 description 24
- 235000010378 sodium ascorbate Nutrition 0.000 description 24
- 238000001542 size-exclusion chromatography Methods 0.000 description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 239000000546 pharmaceutical excipient Substances 0.000 description 20
- 229910052708 sodium Inorganic materials 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000003446 ligand Substances 0.000 description 18
- 239000003085 diluting agent Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 210000005005 sentinel lymph node Anatomy 0.000 description 14
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 11
- 229960005070 ascorbic acid Drugs 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 229910052713 technetium Inorganic materials 0.000 description 11
- 230000002378 acidificating effect Effects 0.000 description 10
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 9
- 239000011668 ascorbic acid Substances 0.000 description 9
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 9
- 239000007974 sodium acetate buffer Substances 0.000 description 9
- 239000001488 sodium phosphate Substances 0.000 description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012669 liquid formulation Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000001632 sodium acetate Substances 0.000 description 8
- 235000017281 sodium acetate Nutrition 0.000 description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- 229960002442 glucosamine Drugs 0.000 description 7
- 239000000084 colloidal system Substances 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 239000004067 bulking agent Substances 0.000 description 5
- 125000002843 carboxylic acid group Chemical group 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000013583 drug formulation Substances 0.000 description 5
- 239000012216 imaging agent Substances 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229940095064 tartrate Drugs 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 3
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000012931 lyophilized formulation Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012633 nuclear imaging Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000011150 stannous chloride Nutrition 0.000 description 3
- 239000001119 stannous chloride Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000001365 lymphatic vessel Anatomy 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000007944 thiolates Chemical class 0.000 description 2
- CEOQIIPQXIIEQT-PQYRJTSOSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;dihydrate Chemical compound O.O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CEOQIIPQXIIEQT-PQYRJTSOSA-N 0.000 description 1
- JALIROBOQHQXST-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;sodium Chemical compound [Na].SC[C@H](N)C(O)=O JALIROBOQHQXST-DKWTVANSSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241001428384 Zamora Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940007424 antimony trisulfide Drugs 0.000 description 1
- NVWBARWTDVQPJD-UHFFFAOYSA-N antimony(3+);trisulfide Chemical compound [S-2].[S-2].[S-2].[Sb+3].[Sb+3] NVWBARWTDVQPJD-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950009740 molybdenum mo-99 Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- PTIBVSAWRDGWAE-UHFFFAOYSA-K trisodium;phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O PTIBVSAWRDGWAE-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/04—Use of additives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/362,778 | 2009-01-30 | ||
| US12/362,778 US20100196272A1 (en) | 2009-01-30 | 2009-01-30 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| PCT/US2010/000222 WO2010087959A1 (en) | 2009-01-30 | 2010-01-28 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090380A Division JP6040276B2 (ja) | 2009-01-30 | 2015-04-27 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012516328A JP2012516328A (ja) | 2012-07-19 |
| JP5743905B2 true JP5743905B2 (ja) | 2015-07-01 |
Family
ID=42395938
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011547973A Active JP5743905B2 (ja) | 2009-01-30 | 2010-01-28 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2015090380A Active JP6040276B2 (ja) | 2009-01-30 | 2015-04-27 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2016217326A Active JP6509796B2 (ja) | 2009-01-30 | 2016-11-07 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2019071387A Expired - Fee Related JP6833892B2 (ja) | 2009-01-30 | 2019-04-03 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2021015866A Withdrawn JP2021088566A (ja) | 2009-01-30 | 2021-02-03 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015090380A Active JP6040276B2 (ja) | 2009-01-30 | 2015-04-27 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2016217326A Active JP6509796B2 (ja) | 2009-01-30 | 2016-11-07 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2019071387A Expired - Fee Related JP6833892B2 (ja) | 2009-01-30 | 2019-04-03 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
| JP2021015866A Withdrawn JP2021088566A (ja) | 2009-01-30 | 2021-02-03 | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20100196272A1 (enExample) |
| EP (2) | EP2392012B1 (enExample) |
| JP (5) | JP5743905B2 (enExample) |
| KR (2) | KR101713559B1 (enExample) |
| CN (1) | CN102301429A (enExample) |
| AU (1) | AU2010208624B2 (enExample) |
| BR (1) | BRPI1007487A2 (enExample) |
| CA (1) | CA2750230C (enExample) |
| WO (1) | WO2010087959A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| JP6163698B2 (ja) * | 2013-03-21 | 2017-07-19 | 国立大学法人 千葉大学 | マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物 |
| HK1225623A1 (zh) | 2013-07-22 | 2017-09-15 | 纳维迪亚生物制药有限公司 | 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| US10328149B2 (en) | 2014-06-13 | 2019-06-25 | Tenboron Oy | Conjugates comprising an anti-EGFR1 antibody |
| JP6722663B2 (ja) * | 2014-07-17 | 2020-07-15 | オハイオ ステート イノベーション ファウンデーション | マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 |
| US10806803B2 (en) | 2014-07-17 | 2020-10-20 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis |
| EP3744708B1 (en) * | 2014-11-13 | 2023-08-09 | Waters Technologies Corporation | Calibrant for liquid chromatography calibration of labeled n-glycans |
| GB201504064D0 (en) | 2015-03-10 | 2015-04-22 | Accretion Biotechnology Ltd | Method and kits for preparing radionuclide complexes |
| CN106317237B (zh) * | 2015-07-03 | 2019-07-19 | 华中科技大学 | 一种用于spect成像的当归多糖衍生物及其合成方法 |
| CN106188226B (zh) * | 2016-07-04 | 2019-12-24 | 江苏省原子医学研究所 | 一种用于淋巴结检查的大分子显像剂及其制备方法 |
| FR3054445B1 (fr) * | 2016-07-26 | 2019-07-05 | Laboratoires Cyclopharma | Synthese d'une composition d'agent radioactif |
| US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
| US11007272B1 (en) | 2016-10-07 | 2021-05-18 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| JP6329302B2 (ja) * | 2017-05-10 | 2018-05-23 | 国立大学法人千葉大学 | マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物 |
| JP7576334B2 (ja) * | 2019-03-29 | 2024-10-31 | 国立研究開発法人量子科学技術研究開発機構 | 放射性医薬の製造方法及び放射性医薬 |
| JP2023533405A (ja) | 2020-07-08 | 2023-08-03 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成 |
| EP4525882A1 (en) | 2022-05-20 | 2025-03-26 | Navidea Biopharmaceuticals, Inc. | Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker |
| US12404349B2 (en) | 2022-10-03 | 2025-09-02 | Navidea Biopharmaceuticals, Inc. | Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1053508B (it) * | 1970-07-06 | 1981-10-10 | Searle & Co | Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego |
| US4364920A (en) * | 1975-04-30 | 1982-12-21 | Medi-Physics, Inc. | Stable diagnostic reagents |
| US4048296A (en) * | 1975-05-27 | 1977-09-13 | Mallinckrodt, Inc. | Radiopharmaceutical scanning agents |
| JPS5569517A (en) * | 1978-11-20 | 1980-05-26 | Nippon Mejifuijitsukusu Kk | Labelling preparation for labelling of erythrocytes with radio-active technetium |
| SE465907B (sv) | 1984-11-01 | 1991-11-18 | Nyegaard & Co As | Diagnosticeringsmedel innehaallande en paramagnetisk metall |
| US5336762A (en) | 1985-11-18 | 1994-08-09 | Access Pharmaceuticals, Inc. | Polychelating agents for image and spectral enhancement (and spectral shift) |
| US4822594A (en) | 1987-01-27 | 1989-04-18 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
| CS263561B1 (en) | 1987-09-18 | 1989-04-14 | Kery Vladimir | Process for preparing water soluble allylderivatives of oligo and polysaccharides |
| GB8801646D0 (en) * | 1988-01-26 | 1988-02-24 | Nycomed As | Chemical compounds |
| US5328679A (en) * | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
| DD286598A5 (de) | 1989-06-29 | 1991-01-31 | Adw Der Ddr,Zi F. Mulekularbiologie,De | Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere |
| EP0516873A1 (en) * | 1991-06-06 | 1992-12-09 | THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center | A method and kit for protein labelling with 99 mTC |
| US5789578A (en) | 1996-01-11 | 1998-08-04 | Massey University | Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality |
| CA2279349C (en) * | 1996-02-02 | 2007-09-25 | Rhomed Incorporated | Ascorbate-stabilized radiopharmaceutical method and composition |
| US20010055563A1 (en) * | 1999-09-09 | 2001-12-27 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| US6066309A (en) * | 1996-02-02 | 2000-05-23 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| AU5135698A (en) | 1996-11-28 | 1998-06-22 | Nihon Schering K.K. | Contrast compound, contrast medium for mri, and method for mri |
| ATE277642T1 (de) | 1999-05-14 | 2004-10-15 | Univ California | Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
| EP2316922B1 (en) * | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| ES2396368T3 (es) | 2003-03-03 | 2013-02-21 | Dyax Corporation | Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos |
| DK1658848T3 (da) * | 2004-10-29 | 2007-11-26 | Pharma Mar Sa | Formuleringer omfattende ecteinascidin og et disaccharid |
| TWI398272B (zh) * | 2005-03-08 | 2013-06-11 | Intervet Int Bv | 化學定義的安定劑 |
| RU2008117396A (ru) * | 2005-10-04 | 2009-11-10 | Альк-Абелло А/С (Dk) | Твердая вакцинная композиция |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| BRPI0808259A2 (pt) * | 2007-03-05 | 2014-07-08 | Cadila Healthcare Ltd | "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada" |
| US20100196272A1 (en) | 2009-01-30 | 2010-08-05 | Neoprobe Corporation | Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran |
| HK1225623A1 (zh) | 2013-07-22 | 2017-09-15 | 纳维迪亚生物制药有限公司 | 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒 |
| EP3169336A4 (en) | 2014-07-17 | 2018-04-04 | Ohio State Innovation Foundation | Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis |
| JP6722663B2 (ja) | 2014-07-17 | 2020-07-15 | オハイオ ステート イノベーション ファウンデーション | マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 |
-
2009
- 2009-01-30 US US12/362,778 patent/US20100196272A1/en not_active Abandoned
-
2010
- 2010-01-28 EP EP10736135.4A patent/EP2392012B1/en active Active
- 2010-01-28 CA CA2750230A patent/CA2750230C/en active Active
- 2010-01-28 KR KR1020117020202A patent/KR101713559B1/ko not_active Expired - Fee Related
- 2010-01-28 AU AU2010208624A patent/AU2010208624B2/en not_active Ceased
- 2010-01-28 CN CN2010800062510A patent/CN102301429A/zh active Pending
- 2010-01-28 BR BRPI1007487A patent/BRPI1007487A2/pt not_active IP Right Cessation
- 2010-01-28 JP JP2011547973A patent/JP5743905B2/ja active Active
- 2010-01-28 KR KR1020177005797A patent/KR101765717B1/ko not_active Expired - Fee Related
- 2010-01-28 WO PCT/US2010/000222 patent/WO2010087959A1/en not_active Ceased
- 2010-01-28 EP EP21152405.3A patent/EP3884965A1/en not_active Withdrawn
-
2012
- 2012-05-01 US US13/461,306 patent/US8545808B2/en active Active
-
2013
- 2013-09-27 US US14/039,648 patent/US9439985B2/en active Active
-
2015
- 2015-04-27 JP JP2015090380A patent/JP6040276B2/ja active Active
-
2016
- 2016-08-10 US US15/233,144 patent/US20160347679A1/en not_active Abandoned
- 2016-11-07 JP JP2016217326A patent/JP6509796B2/ja active Active
-
2019
- 2019-04-03 JP JP2019071387A patent/JP6833892B2/ja not_active Expired - Fee Related
-
2021
- 2021-02-03 JP JP2021015866A patent/JP2021088566A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110115148A (ko) | 2011-10-20 |
| EP2392012B1 (en) | 2021-01-20 |
| JP6833892B2 (ja) | 2021-02-24 |
| EP2392012A4 (en) | 2012-11-14 |
| KR20170027874A (ko) | 2017-03-10 |
| US20100196272A1 (en) | 2010-08-05 |
| CN102301429A (zh) | 2011-12-28 |
| JP2021088566A (ja) | 2021-06-10 |
| US20160347679A1 (en) | 2016-12-01 |
| US8545808B2 (en) | 2013-10-01 |
| BRPI1007487A2 (pt) | 2018-02-20 |
| JP2019178133A (ja) | 2019-10-17 |
| JP6040276B2 (ja) | 2016-12-07 |
| CA2750230C (en) | 2018-06-05 |
| JP6509796B2 (ja) | 2019-05-08 |
| JP2012516328A (ja) | 2012-07-19 |
| JP2017066148A (ja) | 2017-04-06 |
| CA2750230A1 (en) | 2010-08-05 |
| EP2392012A1 (en) | 2011-12-07 |
| WO2010087959A1 (en) | 2010-08-05 |
| KR101713559B1 (ko) | 2017-03-08 |
| AU2010208624B2 (en) | 2016-02-04 |
| EP3884965A1 (en) | 2021-09-29 |
| JP2015164933A (ja) | 2015-09-17 |
| US20120213700A1 (en) | 2012-08-23 |
| AU2010208624A1 (en) | 2011-08-25 |
| US9439985B2 (en) | 2016-09-13 |
| KR101765717B1 (ko) | 2017-08-07 |
| US20140023586A1 (en) | 2014-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6040276B2 (ja) | ジエチレントリアミン五酢酸（ｄｔｐａ）−デキストランを放射標識するための組成物 | |
| JP3853354B2 (ja) | 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤 | |
| EP2271373B1 (en) | 99mtc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical | |
| AU7045394A (en) | Technetium-99m labeled peptides for imaging inflammation | |
| CN110227169A (zh) | 一种结构修饰的rgd多肽的核医学药物 | |
| EP1437145A1 (en) | Enhanced scintigraphic imaging agents for imaging of infection and inflammation | |
| IL279478B1 (en) | A preparation containing a somatostatin analog for radiopharmaceutical use | |
| US20250127941A1 (en) | Detection and localization of internal bleeding | |
| JP2021504296A (ja) | テトロホスミン及びその薬学的に許容できる塩を含む医薬組成物 | |
| Núñez et al. | Combining dose and injection volume for good performance of a specific radiopharmaceutical for sentinel node detection | |
| Cohen | Inertly labeled monoclonal antibodies for PET and optical imaging: unique tools to support antibody development and application in cancer therapy | |
| Peter Laverman et al. | 2 A novel method to label liposomes with Tc-99m by the hydrazino nicotinyl derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140207 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140502 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140606 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140613 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140704 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140807 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150227 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150325 |
|
| R155 | Notification before disposition of declining of application |
Free format text: JAPANESE INTERMEDIATE CODE: R155 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150428 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5743905 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |